Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
- The entries summarize the cited US FDA Egrifta labels for the approved HIV-associated lipodystrophy indication.
- Egrifta SV: 1.4 mg SC once daily from the 2-mg/vial formulation.
- Egrifta WR (approved Apr 2025): 1.28 mg SC once daily from the 11.6-mg single-patient-use multidose vial.
- Egrifta SV and Egrifta WR are NOT interchangeable or substitutable. Different vial sizes, reconstitution procedures, deliverable doses, and administration devices.
- Subcutaneous administration into the abdomen with site rotation per label instructions.